Replies to post #75542 on Biotech Values

[iwfal]

interestingly this HBV thread reminds us of that fact (that while efficacy in HBV is limited for interferon, only interferon - not direct agents, even after prolonged levels of undetectable HBV often - can achieve a sustained response in HBV)

a) Does anyone know of a naturally long term viral infection (i.e. a chronic stage) which does not have high relapse rates when treated with just direct anti-virals? Or will HCV be the first (if it succeeds)?

b) Is a sustained viral response actually necessary? (e.g. in HBV seroconversion of e is considered adequate to prevent more sequelae. Or is that just 'settling'? Will 'settling be accepted for HCV?)

[tony111]

If you believe in the limited distribution of IL-29r and the phase 1 preliminary data, I do think interferon lambda monotherapy will have less side effects than direct anti virals. Does it concern you that Zymo is enrolling another cohort at 0.5mg ? I do hope its a sign that interferon lambda is too potent so its difficult to access the minimum effective dose :)